Experimental biology

Cue Biopharma to Present at Two February 2023 Scientific Conferences

Retrieved on:

Wednesday, February 1, 2023

Federation, FASEB, Conference, Experimental biology, Selective, The FASEB Journal, Cue, Pharmaceutical industry, Management

BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that its President and Chief Scientific Officer, Anish Suri, Ph.D., will participate in two scientific conferences this February, the Immuno-Oncology 360 o Summit, taking place February 7-10 in New York, NY, and the Federation of American Societies for Experimental Biology (FASEB) Catalyst Conference , taking place virtually February 8-9, 2023.

Key Points:

BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that its President and Chief Scientific Officer, Anish Suri, Ph.D., will participate in two scientific conferences this February, the Immuno-Oncology 360 o Summit, taking place February 7-10 in New York, NY, and the Federation of American Societies for Experimental Biology (FASEB) Catalyst Conference , taking place virtually February 8-9, 2023.
Dr. Suri will present an overview of Cue Biopharma’s Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform and interleukin 2 (IL-2)-based CUE-100 series of biologics designed to enable selective targeting of IL-2 to tumor-specific T cells.
Presenter: Anish Suri, Ph.D., president and chief scientific officer, Cue Biopharma
Presenter: Anish Suri, Ph.D., president and chief scientific officer, Cue Biopharma

Pain Intensity in Sickle Cell Disease

Retrieved on:

Monday, November 14, 2022

Pain, characterized by episodes of acute pain, is a hallmark symptom of individuals living with sickle cell disease, resulting in acute health care utilization.

Key Points:

Pain, characterized by episodes of acute pain, is a hallmark symptom of individuals living with sickle cell disease, resulting in acute health care utilization.
The goal of this study was to examine the association among haplotypes of COMT and DRD3 single nucleotide polymorphisms with pain intensity and pain-related acute care utilization in sickle cell disease.
Identification of genetic contributions to pain may result in a greater understanding of sickle cell disease pain and may lead to improved medical management.
Although sickle cell disease was first recognized over 100 years ago, progress in therapies have lagged significantly, with pain continuing to be the hallmark symptom for over 100,000 Americans living with sickle cell disease.

Genomic transposable elements modify the progression of Parkinson's disease

Retrieved on:

Tuesday, November 8, 2022

This study, led by Dr. Koks, analyzed the variation of transposable elements and their impact on different trajectories of Parkinson's disease.

Key Points:

This study, led by Dr. Koks, analyzed the variation of transposable elements and their impact on different trajectories of Parkinson's disease.
This allowed them to develop a comprehensive genomic screen for the transposable elements in these patients.
Some transposable elements predicted faster progression of the disease, with very fast deterioration of motor or cognitive functions.
At the same time, some transposable elements were protective and associated with a slower disease progression suggesting a slowing of neuronal loss and neurodegeneration.

Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference

Retrieved on:

Friday, September 9, 2022

Leveraging its proprietary CINtech platform, Volastra discovered that CIN-high cancer cells are more dependent on chromosome alignment machinery like KIF18A and are thus more vulnerable to KIF18A inhibition than normal cells.

Key Points:

Leveraging its proprietary CINtech platform, Volastra discovered that CIN-high cancer cells are more dependent on chromosome alignment machinery like KIF18A and are thus more vulnerable to KIF18A inhibition than normal cells.
These findings set our KIF18A inhibitor apart from traditional chemotherapies, which can have a detrimental impact on healthy cells.
We anticipate initiating a Phase 1 study for this potential best-in-class KIF18A inhibitor in the second half of 2023.
These new data from Volastras KIF18A inhibitor further support the promise of developing new and better cancer therapies through a deep understanding of this vulnerability.

New Study Finds Mouse Embryonic Stem Cells Have No Special Requirement for Threonine

Retrieved on:

Wednesday, September 7, 2022

The study, led by Dr. Jian Feng in the Department of Physiology and Biophysics at the State University of New York, Buffalo, finds that mouse embryonic stem cells do not have a unique requirement for threonine.

Key Points:

The study, led by Dr. Jian Feng in the Department of Physiology and Biophysics at the State University of New York, Buffalo, finds that mouse embryonic stem cells do not have a unique requirement for threonine.
An influential study published in 2009 claims that the growth and proliferation of mouse embryonic stem cells (mESCs) have a unique dependence on threonine.
It has become accepted that mESCs have a special requirement for threonine to grow and multiply.
The present study thus set the record straight on the amino acid requirement of mESCs by finding that, just like most types of cells, mESCs do not have a special requirement for threonine.

Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022

Retrieved on:

Tuesday, September 6, 2022

The poster will be presented by the lead author of the study and Antibe academic collaborator, James R.W.

Key Points:

The poster will be presented by the lead author of the study and Antibe academic collaborator, James R.W.
Im delighted to have the opportunity to share our clinical data at PAINWeek, commented Dr. Glanville.
Held annually, the PAINWeek National Conference is the largest U.S. conference for frontline healthcare professionals with an interest in pain management.
Antibes lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids and todays NSAIDs for acute pain.

New Study Identifies Higher COVID-19 Viral Loads in American Indians and Alaskan Natives

Retrieved on:

Tuesday, August 16, 2022

Several studies have found that detection of SARS-CoV-2 in peripheral blood is associated with the development of severe COVID-19 and mortality.

Key Points:

Several studies have found that detection of SARS-CoV-2 in peripheral blood is associated with the development of severe COVID-19 and mortality.
However, data are largely unreported for SARS-CoV-2 viral load dynamics and COVID-19 severity in some groups of patients.
The group found that the strongest predictor of severe COVID-19 in the study population was the average viral load in peripheral blood.
Further, they demonstrated that those who self-reported as American Indian and or Alaska Native had more severe COVID-19 and higher peripheral blood viral load.

Potential Risk for Methadone Treatment in Pregnancy

Retrieved on:

Wednesday, July 13, 2022

WASHINGTON, July 13, 2022 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine ( Volume 247, Issue 12, June, 2022 ) identifies a potential risk to using Methadone treatment for opioid dependency in pregnancy.

Key Points:

WASHINGTON, July 13, 2022 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine ( Volume 247, Issue 12, June, 2022 ) identifies a potential risk to using Methadone treatment for opioid dependency in pregnancy.
Methadone (MTD) is commonly prescribed to treat opioid dependency in pregnancy.
Animal studies suggest a link between in-utero MTD exposure and impaired brain white matter development.
This, and prior studies by others, provides support for the idea that methadone treatment for opioid use disorder leads to impaired myelination in the developing brain.

Beam Therapeutics to Present First Research Highlighting Approach to Develop Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant

Retrieved on:

Monday, June 27, 2022

Beam has laid out a long-term strategy to support broad accessibility of base editing treatments for patients with SCD and other hematologic diseases.

Key Points:

Beam has laid out a long-term strategy to support broad accessibility of base editing treatments for patients with SCD and other hematologic diseases.
A key component of this strategy is focused on improving the safety of conditioning regimens, a required pretreatment for patients receiving ex vivo gene editing treatment via autologous transplant.
Todays conditioning regimens rely on nonspecific chemotherapy or radiation, which are associated with significant toxicities, including genotoxicity, primary or secondary malignancy, and organ toxicities including infertility.
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines.

Study Identifies New DNA Clues for Parkinson's Disease Risk

Retrieved on:

Wednesday, June 15, 2022

For many years the search for DNA risk factors to specific diseases, including Parkinson's Disease, has focused on the 2% of our genome known as exons that encode the information for proteins.

Key Points:

For many years the search for DNA risk factors to specific diseases, including Parkinson's Disease, has focused on the 2% of our genome known as exons that encode the information for proteins.
It is now clear the bulk of the DNA risk resides in the other 98% of the genome that determines where, when and for how long exons are produced to generate these proteins.
In this study, Dr. Koks and colleagues analyzed these introns and investigated the changes in them over time correlating with Parkinson's disease progression.
There work illustrates additional blood-based biomarkers that have the potential to be predictive of risk and diagnostic for progression of Parkinson's disease."